You are here

Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41DE025789-01
Agency Tracking Number: R41DE025789
Amount: $149,963.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIDCR
Solicitation Number: PA14-072
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-01-08
Award End Date (Contract End Date): 2018-01-07
Small Business Information
Santa Barbara, CA 93101-2507
United States
DUNS: 078871379
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (513) 247-0320
Business Contact
Phone: (530) 913-2704
Research Institution

DESCRIPTION provided by applicant Infectious bone disease is a major cause of morbidity and mortality worldwide Successful treatment often requires surgical intervention with longer term antibiotic therapy Bacterial biofilm pathogens are associated with most osseous infections and represent a major target of therapy The biofilm pathogens associated with chronic bone infections bind to and colonize on bone surfaces Bisphosphonates BPs are widely used antiresorptive medications that also bind to bone surfaces and have therefore been utilized to treat lytic bone pathoses like osteoporosis multiple myeloma and metastatic bone disease Consequently we hypothesize that using a BP chemical moiety as a vector for the delivery of the antimicrobial agent ciprofloxacin CF to bone surfaces where biofilm pathogens reside could represent a pharmacologically advantageous approach to the treatment of infectious bone disease in the jaw Therefore in this Phase I STTR project we propose to develop a novel BP ciprofloxacin conjugate BP CF using a releasable linker chemistry strategy for targeted bone delivery to effectively treat jawbone infections To avoid any potential effects of BP therapy on bone remodelling or adverse events we will utilize a pharmacologically inert BP that possesses strong bone affinity and will serve as a safe vector for the delivery and release of the antimicrobial agent This will allow for the greatest translational clinical potential in future development of this technology The use of a non pharmacologically active BP will also be helpful in delineating the source of activity in our proposed assays in order to directly study the
effects of the antimicrobial agent with minimal confounders This project will be carried out as a collaborative between BioVinc r LLC Dr Ebetino and USC Prof Sedghizadeh Dr Ebetino and BioVincandapos s main focus is BP chemistry and biology as well as design and synthesis of bisphosphonate based drug delivery systems and imaging probes Prof Sedghizadeh and his collaborators will bring their expertise and capabilities in biofilm microbiology and in novel in vitro and in vivo models of osteolytic infections to this project Prof C E McKenna Ph D University of Southern California an authority on bisphosphonate chemistry and andquot magic linkerandquot technology key inventor Prof R K Boeckman University of Rochester an expert in synthetic organic chemistry and synthesis of bisphosphonate analogs and Prof M N Neely Childrenandapos s Hospital Los Angeles an experienced clinician scientist in the field of pharmacokinetics and infectious diseases will also participate as consultants Our transdisciplinary team is uniquely poised to develop and test the novel BP CF compound for targeted therapeutics for infectious bone disease

PUBLIC HEALTH RELEVANCE The proposed research addresses an important and unmet medical need in the treatment of bone infectious diseases e g jaw infections In a partnership involving BioVinc LLC and the Ostrow School of Dentistry at the University of Southern California the novel bisphosphonate BP ciprofloxacin prodrug conjugate will be synthesized and investigated for biofilm mediated osteolytic infection treatment in an in vitro and in vivo animal model The outcome of this study will be the generation of the novel BP antimicrobial prodrug specifically targeting and delivering the antimicrobial agent to infected bone sites with the goal of developing a highly potent and specific therapeutic treatment for preclinical research
and ultimately clinical applications

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government